ONCT News and Press, Oncternal Therapeutics Inc. From 12/10/20

Oncternal Therapeutics (ONCT) -25% on increasing previously announced bought deal offer to $75.0M.GeoVax Labs (GOVX) -23%.Xenetic Biosciences (XBIO) -21%. on launching $6M registered direct offering priced at-the-market.Savara (SVRA) -19% on providing pipeline and business...

SAN DIEGO, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that due to demand, the underwriter has agreed to increase the size of the previously ...

SAN DIEGO, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC...

Gainers: Obalon Therapeutics (OBLN) +121%.Greenland Technologies (GTEC) +79%.Oncternal Therapeutics (ONCT) +61%.Eastman Kodak (KODK) +60%.Fate Therapeutics (FATE) +46%.Nkarta (NKTX) +44%.Constellation Pharmaceuticals (CNST) +34%.Gamida Cell (GMDA) +31%.EHang Holdings (EH) +30%.Tonix...

Gainers: Obalon Therapeutics (OBLN) +116%, Oncternal Therapeutics (ONCT) +77%, Fate Therapeutics (FATE) +41%, Constellation Pharmaceuticals (CNST) +33%, Nkarta (NKTX) +28%.Losers: scPharmaceuticals (SCPH) -33%, Aptose Biosciences (APTO) -...

Are These On Your List Of Penny Stocks To Buy Right Now? The week has started mixed for broader markets but has that impacted all penny stocks today? In short, no and this has been the case forever. One of the attractions to these cheap stocks is that they tend to move on their own ...

Eastman Kodak (KODK) +76%. as DFC says no laws were broken.Greenland Technologies Holding (GTEC) +60% on launching 'electric industrial vehicle market' divisionObalon Therapeutics (OBLN) +52%.Oncternal Therapeutics (ONCT) +27% on presentation of interim phase 1/2 data...

Oncternal Therapeutics (ONCT) announces updated interim clinical data from the ongoing Phase 1/2 CIRLL clinical trial. "The interim data from the combination of cirmtuzumab and ibrutinib are quite promising in relapsed/refractory (r/r) MCL, with an impressive 87% best ORR that has improv...

Best objective response rate of 87% reported for 15 patients with relapsed/refractory mantle cell lymphoma, with a median follow-up of 12.1 months. Median progression-free survival (PFS) was not reached The combination of c irmtuzumab and ibrutinib has been wel...

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Stocks ended lower on Friday on raised concerns over the economic impact of the pandemic and the Treasury Department's new curtailing of emergency economic...